Suppr超能文献

用于细胞外蛋白溶酶体降解的整合素靶向嵌合体(ITACs)的开发。

Development of Integrin Targeting Chimeras (ITACs) for the Lysosomal Degradation of Extracellular Proteins.

作者信息

Zhou Yaxian, Liao Yaxian, Zhao Yuan, Tang Weiping

机构信息

Lachman Institute of Pharmaceutical Development, School of Pharmacy, University of Wisconsin-Madison, Madison, WI, 53705, USA.

Department of Chemistry, University of Wisconsin-Madison, Madison, WI, 53706, USA.

出版信息

ChemMedChem. 2024 Dec 16;19(24):e202300643. doi: 10.1002/cmdc.202300643. Epub 2024 Oct 29.

Abstract

The emerging of lysosomal targeting chimera (LYTAC) expands the field of targeted protein degradation (TPD) to include the extracellular proteins for precise depletion. However, most of the reported LYTACs either induce ubiquitous degradation of the protein of interest (POI) in a broad range of tissues or specifically target liver cells. More tissue-selective degraders are highly desirable. Herein, we describe the development of cyclic RGD (cRGD) peptide-antibody conjugates as a novel class of integrin targeting chimeras (ITACs) with potential cancer selectivity. Our results indicate that the ITACs are able to recruit integrin to induce the degradation of both soluble and membrane targets in the lysosome. We observed higher efficiency of ITACs on degrading membrane protein in cancer cells, providing a promising platform for cancer-selective TPD strategy.

摘要

溶酶体靶向嵌合体(LYTAC)的出现将靶向蛋白质降解(TPD)领域扩展到包括细胞外蛋白,以实现精确清除。然而,大多数已报道的LYTACs要么在广泛的组织中诱导目的蛋白(POI)的普遍降解,要么特异性靶向肝细胞。非常需要更多具有组织选择性的降解剂。在此,我们描述了环状RGD(cRGD)肽-抗体缀合物作为一类新型整合素靶向嵌合体(ITACs)的开发,其具有潜在的癌症选择性。我们的结果表明,ITACs能够募集整合素以诱导溶酶体中可溶性和膜靶标的降解。我们观察到ITACs在癌细胞中降解膜蛋白的效率更高,为癌症选择性TPD策略提供了一个有前景的平台。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5310/11649485/2dc81c1ab170/nihms-2022085-f0002.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验